1. Home
  2. AXR vs HURA Comparison

AXR vs HURA Comparison

Compare AXR & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMREP Corporation

AXR

AMREP Corporation

HOLD

Current Price

$25.53

Market Cap

136.8M

Sector

Real Estate

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$1.97

Market Cap

144.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXR
HURA
Founded
1961
2009
Country
United States
United States
Employees
49
22
Industry
Homebuilding
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
136.8M
144.3M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
AXR
HURA
Price
$25.53
$1.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$30.00
$9.50
AVG Volume (30 Days)
12.6K
466.3K
Earning Date
03-12-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
89.60
N/A
EPS
1.68
N/A
Revenue
$12,831,000.00
N/A
Revenue This Year
$10.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$0.41
52 Week High
$29.01
$3.90

Technical Indicators

Market Signals
Indicator
AXR
HURA
Relative Strength Index (RSI) 45.23 37.34
Support Level $23.76 $1.66
Resistance Level $28.68 $2.20
Average True Range (ATR) 1.33 0.20
MACD 0.01 -0.05
Stochastic Oscillator 27.45 7.22

Price Performance

Historical Comparison
AXR
HURA

About AXR AMREP Corporation

Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: